Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) – A Cost-Utility Model for the United Kingdom
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2626
https://www.valueinhealthjournal.com/article/S1098-3015(14)04575-6/fulltext
Title :
Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) – A Cost-Utility Model for the United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04575-6&doi=10.1016/j.jval.2014.08.2626
First page :
A382
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
325